Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiency
The transdermal delivery system (TDS) is able to obtain a systemic therapeutic effect by administration through the skin, which has low side effects and is able to maintain a sustained blood concentration. However, due to the barrier presented by the stratum corneum, numerous drugs have poor percuta...
Gespeichert in:
Veröffentlicht in: | Molecular medicine reports 2014-08, Vol.10 (2), p.593-598 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 598 |
---|---|
container_issue | 2 |
container_start_page | 593 |
container_title | Molecular medicine reports |
container_volume | 10 |
creator | CHEN, BIN LIU, DA-LIE PAN, WEN-YAN YANG, XIAO-HUI SHOU, JIA-BAO WU, JU-HUA MAO, QING-LONG WANG, JIA |
description | The transdermal delivery system (TDS) is able to obtain a systemic therapeutic effect by administration through the skin, which has low side effects and is able to maintain a sustained blood concentration. However, due to the barrier presented by the stratum corneum, numerous drugs have poor percutaneous permeability. Therefore, the improvement of skin permeability is key to TDS. The main method of promoting transdermal absorption is through the usage of penetration enhancers. Dimethyl sulfoxide (DMSO) is a commonly used penetration enhancer, which has anti-inflammatory analgesic effects and is able to penetrate the skin. Retinoic acid (RA) and lipolanthionine peptide (LP) may also benefit the permeation efficiency of TDS. Therefore, the present study examined the function of DMSO, RA and LP as penetration enhancers in TDS. Firstly, the optimum concentration of DMSO was confirmed by detecting the expression of the LacZ gene in vitro. Secondly, different combinations of LP, RA and DMSO were applied to mouse skin to analyze the penetration enhancer combination with the greatest efficacy. All the animals were divided into five groups: The RA + LP + DMSO + pORF-LacZ group, the RA + DMSO + pORF-LacZ group, the LP + DMSO + pORF-LacZ group, the DMSO + pORF-LacZ group and the control group. Skin was soaked in combinations of LP, RA and DMSO for seven days and then the pORF-LacZ plasmids were daubed onto the skin once daily three days. On the 11th day, all the animals were sacrificed by cervical dislocation and the skin and blood samples were collected. The blood samples were used to detect the expression of the LacZ gene by quantitative polymerase chain reaction and the skin samples were used to detect the expression of claudin-4 and zonula occluden-1 (ZO-1) proteins by immunohistochemistry and western blot analysis. The results demonstrated that the combination of LP, RA and DMSO exhibited the greatest transdermal delivery efficiency, which verified that RA and LP were able to increase the penetration effects. Following treatment with LP, the symptoms of dermal edema were relieved and the capillaries contracted, which suggested that LP was a safe and effective penetration enhancer able to reduce the side-effects caused by DMSO. The present study provides a guideline for the synthesis of novel penetration enhancers. |
doi_str_mv | 10.3892/mmr.2014.2251 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4094769</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A427301033</galeid><sourcerecordid>A427301033</sourcerecordid><originalsourceid>FETCH-LOGICAL-c580t-53f2b99b069588121f09865759c5cfc4f65b0bd66a244539bcf0c99f623dd9013</originalsourceid><addsrcrecordid>eNptkk2LFDEQhhtR3HX16FUCHvSwPea7O5eFZfELFry455BOV3YyppM26VmYf2-GGUdXJIcUlafeShVv07wmeMV6RT9MU15RTPiKUkGeNOekU6RlGPOnx5gq1Z01L0rZYCwFFep5c0Z5L_qOqvNmc1cAJYeCn1MwcVn7FH0ENMO8-BEukUFLCqEN_gegDLamU0YU-bj2g6_xJYK4NtFCQUs2sYyQJxPQCME_QN4hcM5bD9HuXjbPnAkFXh3vi-bu08fvN1_a22-fv95c37ZW9HhpBXN0UGrAUom-J5Q4rHopOqGssM5yJ8WAh1FKQzkXTA3WYauUk5SNo8KEXTRXB915O0wwWoj1Y0HP2U8m73QyXj9-iX6t79OD5ljxTqoq8P4okNPPLZRFT75YCHU_kLZFE8GEpIp0oqJv_0E3aZtjHU8TxSiXknTkD3VvAmgfXap97V5UX3PaMUwwY5Va_YeqZ4TJ2xTB-Zp_VNAeCmxOpWRwpxkJ1ntz6GoOvTeH3puj8m_-XsyJ_u2GCrw7AGU2cfRjKiemKrUEt5i2WCjGfgEGp8HA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932466171</pqid></control><display><type>article</type><title>Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiency</title><source>Spandidos Publications Journals</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>CHEN, BIN ; LIU, DA-LIE ; PAN, WEN-YAN ; YANG, XIAO-HUI ; SHOU, JIA-BAO ; WU, JU-HUA ; MAO, QING-LONG ; WANG, JIA</creator><creatorcontrib>CHEN, BIN ; LIU, DA-LIE ; PAN, WEN-YAN ; YANG, XIAO-HUI ; SHOU, JIA-BAO ; WU, JU-HUA ; MAO, QING-LONG ; WANG, JIA</creatorcontrib><description>The transdermal delivery system (TDS) is able to obtain a systemic therapeutic effect by administration through the skin, which has low side effects and is able to maintain a sustained blood concentration. However, due to the barrier presented by the stratum corneum, numerous drugs have poor percutaneous permeability. Therefore, the improvement of skin permeability is key to TDS. The main method of promoting transdermal absorption is through the usage of penetration enhancers. Dimethyl sulfoxide (DMSO) is a commonly used penetration enhancer, which has anti-inflammatory analgesic effects and is able to penetrate the skin. Retinoic acid (RA) and lipolanthionine peptide (LP) may also benefit the permeation efficiency of TDS. Therefore, the present study examined the function of DMSO, RA and LP as penetration enhancers in TDS. Firstly, the optimum concentration of DMSO was confirmed by detecting the expression of the LacZ gene in vitro. Secondly, different combinations of LP, RA and DMSO were applied to mouse skin to analyze the penetration enhancer combination with the greatest efficacy. All the animals were divided into five groups: The RA + LP + DMSO + pORF-LacZ group, the RA + DMSO + pORF-LacZ group, the LP + DMSO + pORF-LacZ group, the DMSO + pORF-LacZ group and the control group. Skin was soaked in combinations of LP, RA and DMSO for seven days and then the pORF-LacZ plasmids were daubed onto the skin once daily three days. On the 11th day, all the animals were sacrificed by cervical dislocation and the skin and blood samples were collected. The blood samples were used to detect the expression of the LacZ gene by quantitative polymerase chain reaction and the skin samples were used to detect the expression of claudin-4 and zonula occluden-1 (ZO-1) proteins by immunohistochemistry and western blot analysis. The results demonstrated that the combination of LP, RA and DMSO exhibited the greatest transdermal delivery efficiency, which verified that RA and LP were able to increase the penetration effects. Following treatment with LP, the symptoms of dermal edema were relieved and the capillaries contracted, which suggested that LP was a safe and effective penetration enhancer able to reduce the side-effects caused by DMSO. The present study provides a guideline for the synthesis of novel penetration enhancers.</description><identifier>ISSN: 1791-2997</identifier><identifier>EISSN: 1791-3004</identifier><identifier>DOI: 10.3892/mmr.2014.2251</identifier><identifier>PMID: 24858729</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><subject>Administration, Cutaneous ; Analgesics ; Analysis ; Animals ; Blood levels ; Capillaries ; Claudin-4 - metabolism ; Control ; Dimethyl sulfoxide ; Dimethyl Sulfoxide - pharmacology ; Dislocation ; Drug delivery ; Drug delivery systems ; Drugs ; Edema ; Efficiency ; Enhancers ; Health aspects ; Immunohistochemistry ; Inflammation ; LacZ gene ; Ligands ; lipolanthionine peptide ; Mice ; Mice, Inbred BALB C ; Pathogens ; Peptides - pharmacology ; Permeability ; Permeability - drug effects ; Physiological aspects ; Plasmids ; Plasmids - genetics ; Plasmids - metabolism ; Polymerase chain reaction ; Proteins ; Retinoic acid ; Side effects ; Signal transduction ; Skin ; Skin - drug effects ; Skin - pathology ; Stratum corneum ; toll-like receptor 2 ; Toll-Like Receptor 2 - antagonists & inhibitors ; Toll-Like Receptor 2 - metabolism ; Toll-like receptors ; transdermal delivery system ; Transdermal medication ; Tretinoin ; Tretinoin - pharmacology ; Zonula occludens-1 protein ; Zonula Occludens-1 Protein - metabolism</subject><ispartof>Molecular medicine reports, 2014-08, Vol.10 (2), p.593-598</ispartof><rights>Copyright © 2014, Spandidos Publications</rights><rights>COPYRIGHT 2014 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2014</rights><rights>Copyright © 2014, Spandidos Publications 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c580t-53f2b99b069588121f09865759c5cfc4f65b0bd66a244539bcf0c99f623dd9013</citedby><cites>FETCH-LOGICAL-c580t-53f2b99b069588121f09865759c5cfc4f65b0bd66a244539bcf0c99f623dd9013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,5570,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24858729$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHEN, BIN</creatorcontrib><creatorcontrib>LIU, DA-LIE</creatorcontrib><creatorcontrib>PAN, WEN-YAN</creatorcontrib><creatorcontrib>YANG, XIAO-HUI</creatorcontrib><creatorcontrib>SHOU, JIA-BAO</creatorcontrib><creatorcontrib>WU, JU-HUA</creatorcontrib><creatorcontrib>MAO, QING-LONG</creatorcontrib><creatorcontrib>WANG, JIA</creatorcontrib><title>Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiency</title><title>Molecular medicine reports</title><addtitle>Mol Med Rep</addtitle><description>The transdermal delivery system (TDS) is able to obtain a systemic therapeutic effect by administration through the skin, which has low side effects and is able to maintain a sustained blood concentration. However, due to the barrier presented by the stratum corneum, numerous drugs have poor percutaneous permeability. Therefore, the improvement of skin permeability is key to TDS. The main method of promoting transdermal absorption is through the usage of penetration enhancers. Dimethyl sulfoxide (DMSO) is a commonly used penetration enhancer, which has anti-inflammatory analgesic effects and is able to penetrate the skin. Retinoic acid (RA) and lipolanthionine peptide (LP) may also benefit the permeation efficiency of TDS. Therefore, the present study examined the function of DMSO, RA and LP as penetration enhancers in TDS. Firstly, the optimum concentration of DMSO was confirmed by detecting the expression of the LacZ gene in vitro. Secondly, different combinations of LP, RA and DMSO were applied to mouse skin to analyze the penetration enhancer combination with the greatest efficacy. All the animals were divided into five groups: The RA + LP + DMSO + pORF-LacZ group, the RA + DMSO + pORF-LacZ group, the LP + DMSO + pORF-LacZ group, the DMSO + pORF-LacZ group and the control group. Skin was soaked in combinations of LP, RA and DMSO for seven days and then the pORF-LacZ plasmids were daubed onto the skin once daily three days. On the 11th day, all the animals were sacrificed by cervical dislocation and the skin and blood samples were collected. The blood samples were used to detect the expression of the LacZ gene by quantitative polymerase chain reaction and the skin samples were used to detect the expression of claudin-4 and zonula occluden-1 (ZO-1) proteins by immunohistochemistry and western blot analysis. The results demonstrated that the combination of LP, RA and DMSO exhibited the greatest transdermal delivery efficiency, which verified that RA and LP were able to increase the penetration effects. Following treatment with LP, the symptoms of dermal edema were relieved and the capillaries contracted, which suggested that LP was a safe and effective penetration enhancer able to reduce the side-effects caused by DMSO. The present study provides a guideline for the synthesis of novel penetration enhancers.</description><subject>Administration, Cutaneous</subject><subject>Analgesics</subject><subject>Analysis</subject><subject>Animals</subject><subject>Blood levels</subject><subject>Capillaries</subject><subject>Claudin-4 - metabolism</subject><subject>Control</subject><subject>Dimethyl sulfoxide</subject><subject>Dimethyl Sulfoxide - pharmacology</subject><subject>Dislocation</subject><subject>Drug delivery</subject><subject>Drug delivery systems</subject><subject>Drugs</subject><subject>Edema</subject><subject>Efficiency</subject><subject>Enhancers</subject><subject>Health aspects</subject><subject>Immunohistochemistry</subject><subject>Inflammation</subject><subject>LacZ gene</subject><subject>Ligands</subject><subject>lipolanthionine peptide</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Pathogens</subject><subject>Peptides - pharmacology</subject><subject>Permeability</subject><subject>Permeability - drug effects</subject><subject>Physiological aspects</subject><subject>Plasmids</subject><subject>Plasmids - genetics</subject><subject>Plasmids - metabolism</subject><subject>Polymerase chain reaction</subject><subject>Proteins</subject><subject>Retinoic acid</subject><subject>Side effects</subject><subject>Signal transduction</subject><subject>Skin</subject><subject>Skin - drug effects</subject><subject>Skin - pathology</subject><subject>Stratum corneum</subject><subject>toll-like receptor 2</subject><subject>Toll-Like Receptor 2 - antagonists & inhibitors</subject><subject>Toll-Like Receptor 2 - metabolism</subject><subject>Toll-like receptors</subject><subject>transdermal delivery system</subject><subject>Transdermal medication</subject><subject>Tretinoin</subject><subject>Tretinoin - pharmacology</subject><subject>Zonula occludens-1 protein</subject><subject>Zonula Occludens-1 Protein - metabolism</subject><issn>1791-2997</issn><issn>1791-3004</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkk2LFDEQhhtR3HX16FUCHvSwPea7O5eFZfELFry455BOV3YyppM26VmYf2-GGUdXJIcUlafeShVv07wmeMV6RT9MU15RTPiKUkGeNOekU6RlGPOnx5gq1Z01L0rZYCwFFep5c0Z5L_qOqvNmc1cAJYeCn1MwcVn7FH0ENMO8-BEukUFLCqEN_gegDLamU0YU-bj2g6_xJYK4NtFCQUs2sYyQJxPQCME_QN4hcM5bD9HuXjbPnAkFXh3vi-bu08fvN1_a22-fv95c37ZW9HhpBXN0UGrAUom-J5Q4rHopOqGssM5yJ8WAh1FKQzkXTA3WYauUk5SNo8KEXTRXB915O0wwWoj1Y0HP2U8m73QyXj9-iX6t79OD5ljxTqoq8P4okNPPLZRFT75YCHU_kLZFE8GEpIp0oqJv_0E3aZtjHU8TxSiXknTkD3VvAmgfXap97V5UX3PaMUwwY5Va_YeqZ4TJ2xTB-Zp_VNAeCmxOpWRwpxkJ1ntz6GoOvTeH3puj8m_-XsyJ_u2GCrw7AGU2cfRjKiemKrUEt5i2WCjGfgEGp8HA</recordid><startdate>20140801</startdate><enddate>20140801</enddate><creator>CHEN, BIN</creator><creator>LIU, DA-LIE</creator><creator>PAN, WEN-YAN</creator><creator>YANG, XIAO-HUI</creator><creator>SHOU, JIA-BAO</creator><creator>WU, JU-HUA</creator><creator>MAO, QING-LONG</creator><creator>WANG, JIA</creator><general>D.A. Spandidos</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140801</creationdate><title>Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiency</title><author>CHEN, BIN ; LIU, DA-LIE ; PAN, WEN-YAN ; YANG, XIAO-HUI ; SHOU, JIA-BAO ; WU, JU-HUA ; MAO, QING-LONG ; WANG, JIA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c580t-53f2b99b069588121f09865759c5cfc4f65b0bd66a244539bcf0c99f623dd9013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Administration, Cutaneous</topic><topic>Analgesics</topic><topic>Analysis</topic><topic>Animals</topic><topic>Blood levels</topic><topic>Capillaries</topic><topic>Claudin-4 - metabolism</topic><topic>Control</topic><topic>Dimethyl sulfoxide</topic><topic>Dimethyl Sulfoxide - pharmacology</topic><topic>Dislocation</topic><topic>Drug delivery</topic><topic>Drug delivery systems</topic><topic>Drugs</topic><topic>Edema</topic><topic>Efficiency</topic><topic>Enhancers</topic><topic>Health aspects</topic><topic>Immunohistochemistry</topic><topic>Inflammation</topic><topic>LacZ gene</topic><topic>Ligands</topic><topic>lipolanthionine peptide</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Pathogens</topic><topic>Peptides - pharmacology</topic><topic>Permeability</topic><topic>Permeability - drug effects</topic><topic>Physiological aspects</topic><topic>Plasmids</topic><topic>Plasmids - genetics</topic><topic>Plasmids - metabolism</topic><topic>Polymerase chain reaction</topic><topic>Proteins</topic><topic>Retinoic acid</topic><topic>Side effects</topic><topic>Signal transduction</topic><topic>Skin</topic><topic>Skin - drug effects</topic><topic>Skin - pathology</topic><topic>Stratum corneum</topic><topic>toll-like receptor 2</topic><topic>Toll-Like Receptor 2 - antagonists & inhibitors</topic><topic>Toll-Like Receptor 2 - metabolism</topic><topic>Toll-like receptors</topic><topic>transdermal delivery system</topic><topic>Transdermal medication</topic><topic>Tretinoin</topic><topic>Tretinoin - pharmacology</topic><topic>Zonula occludens-1 protein</topic><topic>Zonula Occludens-1 Protein - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHEN, BIN</creatorcontrib><creatorcontrib>LIU, DA-LIE</creatorcontrib><creatorcontrib>PAN, WEN-YAN</creatorcontrib><creatorcontrib>YANG, XIAO-HUI</creatorcontrib><creatorcontrib>SHOU, JIA-BAO</creatorcontrib><creatorcontrib>WU, JU-HUA</creatorcontrib><creatorcontrib>MAO, QING-LONG</creatorcontrib><creatorcontrib>WANG, JIA</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular medicine reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHEN, BIN</au><au>LIU, DA-LIE</au><au>PAN, WEN-YAN</au><au>YANG, XIAO-HUI</au><au>SHOU, JIA-BAO</au><au>WU, JU-HUA</au><au>MAO, QING-LONG</au><au>WANG, JIA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiency</atitle><jtitle>Molecular medicine reports</jtitle><addtitle>Mol Med Rep</addtitle><date>2014-08-01</date><risdate>2014</risdate><volume>10</volume><issue>2</issue><spage>593</spage><epage>598</epage><pages>593-598</pages><issn>1791-2997</issn><eissn>1791-3004</eissn><abstract>The transdermal delivery system (TDS) is able to obtain a systemic therapeutic effect by administration through the skin, which has low side effects and is able to maintain a sustained blood concentration. However, due to the barrier presented by the stratum corneum, numerous drugs have poor percutaneous permeability. Therefore, the improvement of skin permeability is key to TDS. The main method of promoting transdermal absorption is through the usage of penetration enhancers. Dimethyl sulfoxide (DMSO) is a commonly used penetration enhancer, which has anti-inflammatory analgesic effects and is able to penetrate the skin. Retinoic acid (RA) and lipolanthionine peptide (LP) may also benefit the permeation efficiency of TDS. Therefore, the present study examined the function of DMSO, RA and LP as penetration enhancers in TDS. Firstly, the optimum concentration of DMSO was confirmed by detecting the expression of the LacZ gene in vitro. Secondly, different combinations of LP, RA and DMSO were applied to mouse skin to analyze the penetration enhancer combination with the greatest efficacy. All the animals were divided into five groups: The RA + LP + DMSO + pORF-LacZ group, the RA + DMSO + pORF-LacZ group, the LP + DMSO + pORF-LacZ group, the DMSO + pORF-LacZ group and the control group. Skin was soaked in combinations of LP, RA and DMSO for seven days and then the pORF-LacZ plasmids were daubed onto the skin once daily three days. On the 11th day, all the animals were sacrificed by cervical dislocation and the skin and blood samples were collected. The blood samples were used to detect the expression of the LacZ gene by quantitative polymerase chain reaction and the skin samples were used to detect the expression of claudin-4 and zonula occluden-1 (ZO-1) proteins by immunohistochemistry and western blot analysis. The results demonstrated that the combination of LP, RA and DMSO exhibited the greatest transdermal delivery efficiency, which verified that RA and LP were able to increase the penetration effects. Following treatment with LP, the symptoms of dermal edema were relieved and the capillaries contracted, which suggested that LP was a safe and effective penetration enhancer able to reduce the side-effects caused by DMSO. The present study provides a guideline for the synthesis of novel penetration enhancers.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>24858729</pmid><doi>10.3892/mmr.2014.2251</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1791-2997 |
ispartof | Molecular medicine reports, 2014-08, Vol.10 (2), p.593-598 |
issn | 1791-2997 1791-3004 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4094769 |
source | Spandidos Publications Journals; MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Administration, Cutaneous Analgesics Analysis Animals Blood levels Capillaries Claudin-4 - metabolism Control Dimethyl sulfoxide Dimethyl Sulfoxide - pharmacology Dislocation Drug delivery Drug delivery systems Drugs Edema Efficiency Enhancers Health aspects Immunohistochemistry Inflammation LacZ gene Ligands lipolanthionine peptide Mice Mice, Inbred BALB C Pathogens Peptides - pharmacology Permeability Permeability - drug effects Physiological aspects Plasmids Plasmids - genetics Plasmids - metabolism Polymerase chain reaction Proteins Retinoic acid Side effects Signal transduction Skin Skin - drug effects Skin - pathology Stratum corneum toll-like receptor 2 Toll-Like Receptor 2 - antagonists & inhibitors Toll-Like Receptor 2 - metabolism Toll-like receptors transdermal delivery system Transdermal medication Tretinoin Tretinoin - pharmacology Zonula occludens-1 protein Zonula Occludens-1 Protein - metabolism |
title | Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiency |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T10%3A59%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20lipolanthionine%20peptide,%20a%20toll-like%20receptor%202%20inhibitor,%20enhances%20transdermal%20delivery%20efficiency&rft.jtitle=Molecular%20medicine%20reports&rft.au=CHEN,%20BIN&rft.date=2014-08-01&rft.volume=10&rft.issue=2&rft.spage=593&rft.epage=598&rft.pages=593-598&rft.issn=1791-2997&rft.eissn=1791-3004&rft_id=info:doi/10.3892/mmr.2014.2251&rft_dat=%3Cgale_pubme%3EA427301033%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932466171&rft_id=info:pmid/24858729&rft_galeid=A427301033&rfr_iscdi=true |